QPPV.COM KNOWLEDGE ASSESSMENT

Trastuzumab Deruxtecan: Classification, Mechanism, Safety and Pharmacovigilance Assessment

Test your understanding of the concepts covered by Trastuzumab Deruxtecan: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which approach is most appropriate for periodic benefit-risk evaluation as trastuzumab deruxtecan expands into additional biomarker-defined indications?

Stratify exposure and outcomes by tumour type, biomarker, dose and regimen where possible, while integrating efficacy and key risks Pool all patients under the single label 'HER2 cancer' to maximise sample size Evaluate only response rates and exclude ILD because it is product-specific Evaluate adverse events without considering duration of benefit or treated population

Question 2 of 10 A case report states only that the patient had 'HER2-negative breast cancer' while receiving trastuzumab deruxtecan. What is the most appropriate pharmacovigilance action?

Clarify the HER2 test result, category and testing method used to support treatment selection Automatically classify the use as medication error Assume that the patient had HER2-positive disease Exclude the case because HER2 status is irrelevant once treatment has started

Question 3 of 10 Which statement best explains the pharmacological relevance of the approximately eight molecules of DXd associated with each antibody?

The high drug-to-antibody ratio is a defining structural feature that contributes to payload delivery and the overall ADC safety profile It proves that the antibody can bind eight different receptors simultaneously It means eight separate products are administered together It prevents intracellular release of the payload

Question 4 of 10 Which statement about trastuzumab deruxtecan and trastuzumab is most accurate for regulatory and pharmacovigilance purposes?

A trastuzumab-derived antibody does not make trastuzumab deruxtecan interchangeable with unconjugated trastuzumab The two products should always be treated as the same medicine because they share an antibody component Trastuzumab deruxtecan has no payload-related adverse effects Only the antibody component determines the safety profile of the ADC

Question 5 of 10 Which sequence most accurately represents the key intracellular steps after trastuzumab deruxtecan reaches a HER2-expressing tumour cell?

HER2 binding, internalisation, lysosomal linker cleavage, DXd release and topoisomerase-I inhibition DXd release in plasma, HER2 binding, nuclear transport and linker reformation HER2 degradation, extracellular linker cleavage, antibody recycling and payload neutralisation Direct DNA binding by the intact ADC followed by extracellular antibody cleavage

Question 6 of 10 A patient receiving trastuzumab deruxtecan develops severe neutropenia while also receiving another myelosuppressive medicine and having marrow involvement. What is the best causality approach?

Assess all plausible contributors using treatment chronology, blood-count trends, disease status and supportive-care information Assign the event exclusively to trastuzumab deruxtecan because it is an ADC Assign the event exclusively to marrow involvement without reviewing treatment timing Exclude the case because more than one possible cause exists

Question 7 of 10 Why should pharmacovigilance analyses retain the exact dose, interval and combination regimen for trastuzumab deruxtecan cases?

Dose and regimen context affects comparability, exposure assessment and attribution of events to the ADC, partner medicine or interaction Dose information is needed only for billing purposes All tumour settings use identical regimens, so the information is redundant Combination partners cannot contribute to adverse events

Question 8 of 10 Why is a report coded only as 'pneumonia' potentially inadequate in a trastuzumab deruxtecan case?

The respiratory syndrome may represent drug-related ILD/pneumonitis, which requires different diagnostic and regulatory assessment Pneumonia is never a valid adverse-event term All pneumonia cases are automatically caused by the ADC Pneumonia has no clinical relevance in oncology patients

Question 9 of 10 Which statement best distinguishes HER2-low or HER2-ultralow disease from HER2-mutant NSCLC for pharmacovigilance purposes?

They represent different biomarker concepts and should not be collapsed into an undifferentiated HER2-positive category They are interchangeable terms for the same level of HER2 protein overexpression HER2-mutant NSCLC is defined only by an immunohistochemical staining score HER2-low disease has no relevance to treatment selection or safety analysis

Question 10 of 10 Which pregnancy case information is most important for a meaningful benefit-risk assessment?

Gestational timing, dosing dates, co-exposures, maternal disease course and fetal or neonatal outcome Only the date of the positive pregnancy test Only the patient's HER2 category Only whether the medicine was administered intravenously

Trastuzumab Deruxtecan: Classification, Mechanism, Safety and Pharmacovigilance Assessment

Cookie Settings